Boston Life Sciences, Inc. Announces Presentation of Cethrin Phase,I/IIa 6-Month Results at 75th Annual Meeting of the American,Association of Neurological Surgeons ( l Injury Association (ASIA) A. That mea...)

HOME >> MEDICINE >> TECHNOLOGY

Boston Life Sciences, Inc. Announces Presentation of Cethrin Phase,I/IIa 6-Month Results at 75th Annual Meeting of the American,Association of Neurological Surgeons

l Injury Association (ASIA) A. That means they suffered a complete thoracic or cervical injury (i.e. having no sensory or motor function below the level of the SCI). ASIA grades are designated from A through E, with 'A' designating complete SCI, and 'E' being normal. Grades 'B' through 'D' designate increasing levels of motor and sensory improvements.

An escalating dose of Cethrin(R) (0.3, 1.0, 3.0, or 6 mg.) was administered to the injured spinal cord during surgical decompression/reconstruction. This occurred within five days of the SCI incident, with the average time being 53 hours. All adverse events were recorded and neurological outcomes were assessed using ASIA standards at 0, 1.5, 3, 6 and 12 months. The following outcomes were noted:

    -- There were no serious adverse effects related to Cethrin(R).

    -- The complete 6-month patient data showed, 28 percent of patients (10 of

       36) improved by one or more ASIA grades as compared to reported

       literature results of 6.7% (Burns, J.Neurotrauma, 2003).

    -- Five patients improved to ASIA C and two patients improved to ASIA D.

       One patient with a thoracic SCI died from acute respiratory distress

       syndrome (ARDS).

About Cethrin

Cethrin is a recombinant protein drug intended to facilitate the re-growth of axons during the critical period immediately after a major injury to the spinal cord. Following an SCI, about two-thirds of patients undergo decompression/stabilization surgery. In this surgery, Cethrin is delivered in a single dose directly onto the injured region of the spinal cord without the need for further invasive procedures. Cethrin has been designated an Orphan Drug.

About Boston Life Sciences

Boston Life Sciences, Inc. (BLSI) is engaged in the research and clinical development of diagnostic and therapeutic products for central nervous system (CNS) disorders. Cethrin(R), a recombinant-protein-based drug designed to promote n
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Boston Scientific Announces Schedule for EuroPcr 2007
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

Post Your Comments:

( l Injury Association (ASIA) A. That mea...)Boston Life Sciences, Inc. Announces Presentation of Cethrin Phase,I/IIa 6-Month Results at 75th Annual Meeting of the American,Association of Neurological Surgeons,Health